Pelthos Therapeutics Stock Performance
| PTHS Stock | 22.99 0.33 1.42% |
The company holds a Beta of 0.52, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pelthos Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Pelthos Therapeutics is expected to be smaller as well. At this point, Pelthos Therapeutics has a negative expected return of -0.49%. Please make sure to check Pelthos Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Pelthos Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pelthos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's technical indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (1.42) | Five Day Return (0.04) | Year To Date Return (21.94) | Ten Year Return 94.83 | All Time Return 94.83 |
1 | Pelthos Therapeutics Inc. Q3 2025 Earnings Call Transcript | 11/14/2025 |
2 | Will Pelthos Therapeutics Inc. stock hit Wall Street targets - 2025 Major Catalysts Entry Point Confirmation Signals - newser.com | 11/19/2025 |
3 | Friedberg of Pelthos Therapeutics sells 280,280 in stock By Investing.com - Investing.com India | 11/26/2025 |
4 | Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference | 12/02/2025 |
5 | Disposition of 9542 shares by Pauls Matthew of Pelthos Therapeutics subject to Rule 16b-3 | 12/10/2025 |
6 | Pelthos Therapeutics Acquires Global Rights to Xeglyze - TipRanks | 01/02/2026 |
7 | Horizon Technology Finance Provides up to 50 Million Venture Loan Facility to Pelthos Therapeutics - FinancialContent | 01/15/2026 |
8 | Pelthos Therapeutics price target raised to 60 from 57 at Oppenheimer - TipRanks | 01/26/2026 |
9 | Acquisition by Malamut Richard of 58230 shares of Pelthos Therapeutics at 13.5 subject to Rule 16b-3 | 01/29/2026 |
10 | Disposition of tradable shares by Ligand Pharmaceuticals Inc of Pelthos Therapeutics at 34.442 subject to Rule 16b-3 | 02/04/2026 |
| Begin Period Cash Flow | 96.4 K | |
| Free Cash Flow | -5.8 M |
Pelthos Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,400 in Pelthos Therapeutics on November 10, 2025 and sell it today you would lose (1,101) from holding Pelthos Therapeutics or give up 32.38% of portfolio value over 90 days. Pelthos Therapeutics is currently does not generate positive expected returns and assumes 5.3174% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Pelthos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pelthos Therapeutics Target Price Odds to finish over Current Price
The tendency of Pelthos Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 22.99 | 90 days | 22.99 | about 85.64 |
Based on a normal probability distribution, the odds of Pelthos Therapeutics to move above the current price in 90 days from now is about 85.64 (This Pelthos Therapeutics probability density function shows the probability of Pelthos Stock to fall within a particular range of prices over 90 days) .
Pelthos Therapeutics Price Density |
| Price |
Predictive Modules for Pelthos Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pelthos Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pelthos Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pelthos Therapeutics is not an exception. The market had few large corrections towards the Pelthos Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pelthos Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pelthos Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.51 | |
β | Beta against Dow Jones | 0.52 | |
σ | Overall volatility | 4.04 | |
Ir | Information ratio | -0.1 |
Pelthos Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pelthos Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pelthos Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pelthos Therapeutics generated a negative expected return over the last 90 days | |
| Pelthos Therapeutics has high historical volatility and very poor performance | |
| Pelthos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Pelthos Therapeutics was previously known as Chromocell Therapeutics and was traded on NYSE MKT Exchange under the symbol CHRO. | |
| Net Loss for the year was (7.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pelthos Therapeutics generates negative cash flow from operations | |
| Pelthos Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of tradable shares by Ligand Pharmaceuticals Inc of Pelthos Therapeutics at 34.442 subject to Rule 16b-3 |
Pelthos Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pelthos Stock often depends not only on the future outlook of the current and potential Pelthos Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pelthos Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 587.6 K | |
| Cash And Short Term Investments | 513.4 K |
Pelthos Therapeutics Fundamentals Growth
Pelthos Stock prices reflect investors' perceptions of the future prospects and financial health of Pelthos Therapeutics, and Pelthos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pelthos Stock performance.
| EBITDA | (7.17 M) | ||||
| Net Income | (7.96 M) | ||||
| Total Debt | 2.19 M | ||||
| Cash Flow From Operations | (5.79 M) | ||||
| Total Asset | 1.37 M | ||||
| Retained Earnings | (21.47 M) | ||||
| Working Capital | (2.71 M) | ||||
About Pelthos Therapeutics Performance
Assessing Pelthos Therapeutics' fundamental ratios provides investors with valuable insights into Pelthos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Pelthos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.23) | (5.49) | |
| Return On Capital Employed | 2.51 | 2.64 | |
| Return On Assets | (5.23) | (5.49) | |
| Return On Equity | 2.64 | 2.77 |
Things to note about Pelthos Therapeutics performance evaluation
Checking the ongoing alerts about Pelthos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pelthos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pelthos Therapeutics generated a negative expected return over the last 90 days | |
| Pelthos Therapeutics has high historical volatility and very poor performance | |
| Pelthos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Pelthos Therapeutics was previously known as Chromocell Therapeutics and was traded on NYSE MKT Exchange under the symbol CHRO. | |
| Net Loss for the year was (7.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pelthos Therapeutics generates negative cash flow from operations | |
| Pelthos Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of tradable shares by Ligand Pharmaceuticals Inc of Pelthos Therapeutics at 34.442 subject to Rule 16b-3 |
- Analyzing Pelthos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pelthos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Pelthos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pelthos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pelthos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pelthos Therapeutics' stock. These opinions can provide insight into Pelthos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pelthos Stock Analysis
When running Pelthos Therapeutics' price analysis, check to measure Pelthos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pelthos Therapeutics is operating at the current time. Most of Pelthos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pelthos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pelthos Therapeutics' price. Additionally, you may evaluate how the addition of Pelthos Therapeutics to your portfolios can decrease your overall portfolio volatility.